iPhone app iPad app Android phone app Android tablet app

Hippa

Disability Insurance: A Blessing or a Burden?

Erin Havel | Posted 05.21.2013 | Healthy Living
Read More: Insurance Denials, Obamacare, Disability Insurance, Erisa, Affordable Care Act, Hippa, Generation Why, Cancer Disability, Cancer Insurance, Cancer Health Care, Healthy Living News
Erin Havel

Insurance is meant to protect a person should the unthinkable occur. However, insurance corporations are expected to turn a large profit and often times denying coverage is a way to gain some of those profits. That, in my mind, is a burden no individual should bear.

Read Whole Story

Sexual Assault Investigations Impeded By Privacy Laws On Campus

The Coloradoan | Laura Frank | Posted 05.25.2011 | Denver
Read More: University, Hippa, Date Rape Drug, Frat, Date Rape, CU Boulder, Privacy Law, Campus, College, University of Colorado, Sexual Assault, Cu, Privacy, Fraternities, Denver News

In the fall of 2008, University of Colorado students who'd sought help from the school's Office of Victim Assistance told counselors they'd been the t...

Read Whole Story

Health Industry Winning Round On Privacy Of Digital Health Records

Huffington Post Investigative Fund | Emma Schwartz | Posted 05.25.2011 | Technology
Read More: Hippa, Digital Health Records, Electronic Medical Records, Technology News

Lobbyists for the health industry are close to a victory over consumer groups in a dispute about when patients should be told their digital medical re...

Read Whole Story

Innovations in Phase IV Clinical Trials for Change in Health Care

Sunil Chacko | Posted 05.25.2011 | Politics
Read More: Big Pharma, Hippa, Congress, Public Health, Fda, Clinical Research, Clinical Trials, Pharmaceutical Companies, Pharmaceutical Industry, Health, Hospitals, Marketing, Doctors, Medicaid, Medicare, Food and Drug Administration, Hmos, Phase Iv, Pharmaceuticals, Hmo, Politics News
Sunil Chacko

For dying patients with no therapy that is working, compassionate use programs exist to provide drugs in phase II or III clinical trials when the patient was ineligible to participate in the trial.

Read Whole Story